Tradestie Institutional Equity Comparison Engine

DMAC vs LXRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical while LXRX counters with relative strength in Options & Structure. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LXRX at N/M Forward P/E and -147.4% operating margin (-20.7% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against LXRX sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DMAC N/M vs LXRX N/M Fwd P/E
Growth & Margin Winner DMAC
Op Margin 0.0% vs -147.4% ยท YoY +0.0% vs -20.7%
Momentum & Technical Winner DMAC
1Y +55.3% vs +21.2% ยท 52W Pos 55% vs 41%
Options & Structure Winner LXRX
SURGE (14th %ile IV) vs BREAKDOWN (8th %ile IV)
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.75
-2.51% 1D
Market Cap $810.3M
1M Return +14.8%
1Y Return +21.18%
Forward P/E N/M
Unified AI Score
37.3 / 100 SELL
Tech 50.0 Fund 33.0 Flow 65.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DMAC +55.26% LXRX +21.18% Spread: +34.08 pp (DMAC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DMAC Revenue LXRX Revenue DMAC Op. Margin LXRX Op. Margin Margin Edge
FY2015 N/A $130M N/A 1.1% LXRX
FY2017 N/A $20M N/A -822.1% LXRX
FY2018 $0M $30M -1352.2% -388.5% LXRX
FY2019 N/A $30M N/A 437.5% LXRX
FY2020 N/A $20M N/A -204.2% LXRX
FY2023 N/A $0M N/A -15473.0% LXRX
FY2024 N/A $10M N/A -3284.7% LXRX
FY2025 N/A $50M N/A -98.2% LXRX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DMAC (5) vs LXRX (3)
Institutional Metric DMAC LXRX Criterion Row Winner
Market Capitalization Scale $503.1M $810.3M Larger Scale LXRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -20.7% Higher Growth DMAC
Operating Margin (TTM) Profitability 0.0% -147.4% Higher Margin DMAC
Net Profit Margin Profitability 0.0% -161.8% Higher Margin DMAC
Return on Equity (ROE) Capital Efficiency -114.6% -43.9% Higher ROE LXRX
52-Week Range Position Momentum 55% ($5โ€“$11) 41% ($1โ€“$3) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 98% Vol 0.62ฮฒ ยท 60% Vol Lower Realized Risk LXRX
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 37.3 / 100 (SELL) Higher Composite DMAC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DMAC vs LXRX Buy Guide
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LXRX BREAKDOWN
98d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live LXRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DMAC nor LXRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.